Clinical Scorecard: Evidence and Justification for the Use of Mesoglycan in Managing Chronic Venous Disease and Hemorrhoidal Disease: A Narrative Review
At a Glance
Category
Detail
Condition
Chronic Venous Disease (CVD) and Hemorrhoidal Disease (HD)
Key Mechanisms
Damage to endothelial glycocalyx and extracellular matrix leading to inflammation, endothelial dysfunction, and structural vein changes; mesoglycan replenishes glycosaminoglycans to restore vascular homeostasis
Target Population
Patients with CVD or HD, including those with symptoms such as leg heaviness, cramps, varicose veins, and hemorrhoidal symptoms
Care Setting
Outpatient and clinical settings focusing on conservative management escalating to surgery if needed
Key Highlights
CVD affects 22–41% and HD affects 11–39% of populations, significantly impacting quality of life.
Mesoglycan is a natural glycosaminoglycan preparation (heparan sulfate, dermatan sulfate, heparin, chondroitin sulfate) used to treat CVD and HD.
Mesoglycan acts by restoring glycocalyx integrity, reducing inflammation, improving endothelial function, and protecting extracellular matrix.
Guideline-Based Recommendations
Diagnosis
Use Clinical–Etiological–Anatomical–Pathological (CEAP) classification for CVD.
Assess symptoms such as leg aching, heaviness, cramps, and visible signs like varicose veins.
Evaluate risk factors including genetics, age, obesity, pregnancy, and history of venous thrombosis.
Management
Start with conservative measures: lifestyle changes, compression therapy for CVD, topical treatments for HD.
Escalate to oral therapies such as mesoglycan for symptomatic relief and pathophysiological modification.
Consider surgery for severe disease impacting health-related quality of life.
Monitoring & Follow-up
Monitor symptom progression and quality of life deterioration.
Assess for complications such as venous ulcers, cellulitis, thromboembolic events, and post-thrombotic syndrome.
Evaluate treatment response and side effects during oral mesoglycan therapy.
Risks
Progressive CVD can lead to serious complications including venous ulcers and thromboembolic events.
Damage to glycocalyx and endothelial dysfunction may exacerbate inflammation and coagulation.
Risk factors such as immobilization and estrogen therapy increase disease severity.
Patient & Prescribing Data
Patients with chronic venous disease or hemorrhoidal disease exhibiting symptoms and structural venous changes.
Mesoglycan provides a multi-GAG approach to restore endothelial glycocalyx, reduce inflammation, and improve vascular function, supporting its use as an oral adjunct in conservative management.
Clinical Best Practices
Implement early conservative treatment including lifestyle modification and compression before oral therapy.
Use mesoglycan to target underlying pathophysiological mechanisms involving glycocalyx and extracellular matrix restoration.
Regularly assess patient symptoms and quality of life to guide treatment escalation.
Educate patients on risk factors and adherence to therapy to prevent disease progression.
